Moderna : 2024 ESCMID (mRNA-1010) - MarketScreener

Safety and Immunogenicity of an mRNA-Based


Seasonal Influenza Vaccine in Healthy Adults


Mieke Soens, Raffael...

Related Keywords

Spain ,United States ,Barcelona ,Comunidad Autonoma De Cataluna ,American ,Jintanat Ananworanich ,Raffael Nachbagauer ,Angela Choi ,Kristi Schaefers ,Andrei Avanesov ,Dolgine Nat ,Aliscia Daniels ,Alicia Pucci ,Karen Chen ,Bryony Hicks ,Carole Henry ,Mieke Soens ,Greg Livermore ,Exchange Commission ,Centers For Disease ,World Health Organization ,European Congress ,Moderna Inc ,Influenza Vaccine ,Healthy Adults ,Clinical Microbiology ,Infectious Diseases ,Good Publication Practice ,Private Securities Litigation Reform Act ,Annual Report ,Based Seasonal Influenza Vaccine Candidate ,World Health ,Wkly Epidemiol ,Rev Drug ,Disease Control ,Vaccine Effectiveness ,How Well Do Flu Vaccines ,Active Controlled Study Evaluating ,Northern Hemisphere ,All Primary Immunogenicity End Points ,Mean Ratios ,Active Comparator ,Rate Differences ,Markets ,